NEW YORK (GenomeWeb News) – Qiagen said after the close of the market Thursday that it has acquired AmniSure International, a privately held point-of-care diagnostics firm, for an undisclosed amount.

Boston-based AmniSure sells an assay for determining whether a pregnant woman is suffering rupture of fetal membranes. Qiagen said as many as 30 percent of pregnant women are checked for this condition in clinical settings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.